Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment

Loading news article.

Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment | WAPE

Freenome And Abbott Receive FDA Approval For The SimpleScreen CRC Blood-Based Screening Option For Colorectal Cancer, With Freenome Earning $100M Milestone Payment

Article summary

Related companies

Comments —